SB297006

Names

[ Name ]:
SB297006

[Synonym ]:
n-benzoyl-4-nitroaniline ethyl ester

Biological Activity

[Description]:

SB297006 is a CCR3 antagonist, which significantly inhibits proliferation and neurosphere formation in CCL11-treated neural progenitor cells.

[Related Catalog]:

Research Areas >> Neurological Disease

[Target]

CCR3[1]

[In Vitro]

SB297006 is a CCR3 antagonist, significantly inhibits proliferation and neurosphere formation in CCL11-treated neural progenitor cells (NPCs) at 100 μM[1].

[Cell Assay]

To evaluate CCR3 blocking, neural progenitor cells (NPCs) are incubated with the CCR3 antagonist SB297006 (100 μM) for 30 minutes and then stimulated with CCL11 (2 μg/mL). After 3 days of culture, NPCs are subjected to CCK-8 assays[1].

[References]

[1]. Wang F, et al. CCL11 promotes migration and proliferation of mouse neural progenitor cells. Stem Cell Res Ther. 2017 Feb 7;8(1):26.

[Related Small Molecules]

INCB3344 | Cenicriviroc | INCB8761(PF-4136309) | RS504393 | RS-102895 hydrochloride | BX 471 | TAK-779 | Vercirnon | MK-0812 Succinate | AZD 2098 | CCX140 | INCB 3284 | ZK 756326 | CCR2-RA-[R] | BMS-813160

Chemical & Physical Properties

[ Melting Point ]:
121 °C

[ Molecular Formula ]:
C₁₈H₁₈N₂O₅

[ Molecular Weight ]:
342.34600

[ Exact Mass ]:
342.12200

[ PSA ]:
101.22000

[ LogP ]:
3.41310

Safety Information

[ Symbol ]:

GHS07, GHS09

[ Signal Word ]:
Warning

[ Hazard Statements ]:
H302-H400

[ Precautionary Statements ]:
P273

[ RIDADR ]:
UN 3077 9 / PGIII

Precursor & DownStream

Precursor

DownStream

Articles

CCR3 antagonists: a survey of the patent literature.

Expert Opin. Ther. Pat. 19(8) , 1109-32, (2009)

Since the mid-1990s, there has been significant effort invested in the discovery and clinical development of CC chemokine receptor-3 (CCR3) antagonists as potential therapeutics for airway disease.A p...

Cytokine modulators as novel therapies for asthma.

Annu. Rev. Pharmacol. Toxicol. 42 , 81-98, (2002)

Cytokines play a critical role in orchestrating and perpetuating inflammation in asthmatic airways and several specific cytokine and chemokine inhibitors are now in development for the treatment of as...